|By PR Newswire||
|September 10, 2012 08:00 AM EDT|
SEATTLE, Sept.10, 2012 /PRNewswire/ -- The Heart Failure Society of America (HFSA) 16th Annual Scientific Meeting will include a Late Breaking News Symposium today. The session will describe the results of recent trials and discuss their implications for the care of patients with heart failure.
Dr. Daniel Burkhoff, M.D., Ph.D, of CircuLite and Columbia University, will present his research on the current clinical experience with the Synergy Micro-Pump system in patients with end stage heart failure during the Late Breaking News Session, as well as during several other academic sessions. This pump has been designed to be used slightly earlier in the disease process than current VAD therapy and, in that setting, appears to provide sufficient mechanical assistance with less adverse effects on the patient.
"We've found that this smaller, less invasive pump has improved the quality of life and even reversed symptoms for a number of heart failure patients," said Dr. Burkhoff. "These findings reflect the need to develop more options for patients who are not quite at the stage where they require conventional VAD therapy, but are suffering from with poor quality of life and effort intolerance."
In addition to Dr. Burkhoff's presentation, the results of several other studies will be presented, including:
- Warfarin versus Aspirin in Patients with Reduced Cardiac Ejection Fraction (WARCEF) Trial
- Study of a Cross-Linked Polyelectrolyte vs. Placebo in Heart Failure Patients with Chronic Kidney Disease
- Improving Self Care Behavior and Clinical Outcomes in Rural Patients with Heart Failure
- PARAMOUNT for Preserved EF Heart Failure
The 16th Annual Scientific Meeting is a four-day forum for heart failure specialists to present research findings and advances in treatment. Presentations will address emerging trends in research and new developments in the approach to treating patients with all stages of heart failure.
For a complete list of annual meeting sessions or for details on attending the conference, call (617) 226-7193 or visit www.hfsa.org and click on Annual Scientific Meeting. There is no registration fee for accredited journalists. Interview areas will be available on-site in addition to a fully-staffed press room with phone and internet accessibility. You may follow news from the meeting on Twitter @HFSA and #HFSA
About Heart Failure
Heart failure is a progressive condition in which the heart muscle becomes weakened after it is injured, most commonly from heart attack or high blood pressure, and gradually loses its ability to pump enough blood to supply the body's needs. Many people are not aware they have heart failure because the symptoms are often mistaken for signs of getting older. Heart failure affects 4.6 to 4.8 million individuals in the United States. Demographic and clinical evidence strongly suggests that the prevalence of heart failure will increase throughout the next decade. Ten to 15 years ago heart failure was considered a "death sentence;" however, recent advances in treatment have shown that early diagnosis and proper care in early stages of the condition are key to slowing, stopping or in some cases reversing progression, improving quality of life, and extending life expectancy. For more information on heart failure, please visit www.abouthf.org.
About the Heart Failure Society of America
The Heart Failure Society of America (HFSA) is a nonprofit educational organization, founded in 1994 as the first organized association of heart failure experts. The HFSA provides a forum for all those interested in heart function, heart failure research and patient care. The Society also serves as a resource for governmental agencies (FDA, NIH, NHLBI, CMS). The HFSA Annual Scientific Meeting is designed to highlight recent advances in the development of strategies to address the complex epidemiological, clinical and therapeutic issues of heart failure. Additional information on HFSA can be found at www.hfsa.org.
SOURCE Heart Failure Society of America